CLL patients exhibit high levels of exhaustion markers such as PD-1, CD244, CD160, CTLA-4, TIM-3, and LAG-3, resulting in diminished expansion and antitumor killing as well as response to CAR-T cells [158,168]. Here, HAVCR2 is linked to B-cell chronic lymphocytic leukemia.